Skin changes on continued imatinib therapy in patients with Ph+ CML

被引：0
|
作者：
Saikia, Tapan [1 ]
Hazarika, Nandim [1 ]
Dhabhar, Boman [1 ]
机构：
[1] Prince Aly Khan Hosp, Bombay, Maharashtra, India
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.2963.2963
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2963
引用
收藏
页码：870A / 870A
页数：1
相关论文
共 50 条
  • [41] Features of megakaryo- and erythropoiesis and the outcome of allogeneic BMT in Ph+ CML
    Kvasnicka, HM
    Thiele, J
    Beelen, D
    Fischer, R
    Schaefer, UW
    BONE MARROW TRANSPLANTATION, 1999, 23 : S60 - S60
  • [42] Response to imatinib in patients with chronic myeloid Leukemia (CML) with variant Philadelphia chromosome (Ph).
    El-Zimaity, MMT
    Kantarjian, HM
    Talpaz, M
    Garcia-Manero, G
    O'Brien, S
    Giles, FJ
    Verstovsek, S
    Ferrajoli, A
    Rios, MB
    Hayes, KJ
    Cortes, JE
    BLOOD, 2002, 100 (11) : 788A - 788A
  • [43] Therapy with imatinib in elderly CML patients (≥65 years): Results of the German CML-Study IV
    Proetel, U.
    Pletsch, N.
    Lauseker, M.
    Jung-Munkwitz, S.
    Mueller, M. C.
    Hanfstein, B.
    Leitner, A.
    Haferlach, C.
    Schlegelberger, B.
    Schnittger, S.
    Ehninger, G.
    Hossfeld, D. K.
    Krause, S. W.
    Nerl, C.
    Pralle, H.
    Heim, D.
    Baerlocher, G. M.
    Balleisen, L.
    Einsele, H.
    Ho, A. D.
    Falge, C.
    M, Haenel
    Pfreundschuh, M.
    Kanz, L.
    Stegelmann, F.
    Koehne, C. -H.
    Kremers, S.
    Spiekermann, K.
    Koschmieder, S.
    Waller, C. F.
    Bentz, M.
    Pfirrmann, M.
    Hochhaus, A.
    Hasford, J.
    Hehlmann, R.
    Saussele, S.
    ONKOLOGIE, 2011, 34 : 185 - 185
  • [44] PHILADELPHIA-NEGATIVE (PH-) CHRONIC MYELOID-LEUKEMIA (CML) - COMPARISON WITH PH+ CML AND CHRONIC MYELOMONOCYTIC LEUKEMIA
    MARTIAT, P
    MICHAUX, JL
    RODHAIN, J
    BLOOD, 1991, 78 (01) : 205 - 211
  • [45] THE EFFICACY OF IMATINIB MESYLATE TREATMENT PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA PH' POSITIVE (CML) REFRACTORY TO PREVIOUSLY INTERFERON THERAPY (CML) - THE OWN POLISH STUDY REPORT
    Ceglarek, B.
    Konopka, L.
    Warzocha, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 577 - 578
  • [46] Questioning the aim of CML therapy in the era of Imatinib?
    Carella, AM
    LEUKEMIA, 2003, 17 (06) : 1199 - 1200
  • [47] Questioning the aim of CML therapy in the era of Imatinib?
    A M Carella
    Leukemia, 2003, 17 : 1199 - 1200
  • [48] HyperCKemia in CML patients on imatinib mesylate
    Hewitt, Joanne D.
    Rusnak, Deborah A.
    Cox-Kenneth, Nanette
    Larratt, Loree M.
    Turner, Robert
    BLOOD, 2007, 110 (11) : 871A - 871A
  • [49] Efficacy and Safety of Imatinib on Top of BFM-Like Chemotherapy in Pediatric Patients with Ph+/BCR-ABL+ Acute Lymphoblastic Leukemia (Ph+ ALL). the EsPhALL Study
    Biondi, Andrea
    Schrappe, Martin
    Di Lorenzo, Paola
    Castor, Anders
    Lucchini, Giovanna
    Gandemer, Virginie
    Pieters, Rob
    Stary, Jan
    Escherich, Gabriele
    Campbell, Myriam
    Ci Kong-Li
    Vora, Ajay J.
    Lonnerholm, Gudmar
    Arico, Maurizio
    Harbott, Jochen
    Saha, Vaskar
    Valsecchi, Maria Grazia
    BLOOD, 2011, 118 (21) : 398 - 398
  • [50] Clinical efficacy and safety of imatinib in the management of Ph+ chronic myeloid or acute lymphoblastic leukemia in Chinese patients
    Zhu, Yu
    Qian, Si-Xuan
    ONCOTARGETS AND THERAPY, 2014, 7 : 395 - 404
12345